Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Shin Hamada

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5111433739, A5157965450. Sources: OpenAlex.

Their work

Papers
43 (first author 9, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2011: 1 paper · 2012: 5 papers · 2013: 5 papers · 2014: 4 papers · 2015: 5 papers · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 5 papers · 2022: 3 papers · 2023: none · 2024: none · 2025: none · 2026: 6 papers

Papers 43

  1. Neoadjuvant and adjuvant treatment for pancreatic ductal adenocarcinoma in patients over 80 years old based on a nationwide clinical database. Co-author DOI 10.1007/s00535-026-02480-8↗
  2. Long-term outcomes of plastic versus metal stents for preoperative biliary drainage in pancreatic cancer: a nationwide propensity score-matched analysis. Co-author DOI 10.1016/j.gie.2026.05.032↗
  3. Utility of longitudinal changes in CA19-9 for detection of pancreatic ductal adenocarcinoma in patients with benign pancreatic diseases. Co-author DOI 10.1016/j.pan.2026.10.007↗
  4. High intrapancreatic fat deposition accelerates pancreatic ductal adenocarcinoma growth and metastasis with enrollment of FABP5 upregulation. Co-author DOI 10.1038/s41598-026-56838-2↗
  5. Clinical Statistics and Outcomes of Pancreatic Neoplasms in Japan: A Retrospective Cohort Study Using the Japan Pancreatic Cancer Registry. Co-author DOI 10.1097/mpa.0000000000002694↗
  6. Type I Collagen Increases Survivin Expression in Pancreatic Cancer Cells. First author DOI 10.1620/tjem.2026.j084↗
  7. Clinical features and prognostic impact of asymptomatic pancreatic cancer. Co-author DOI 10.1038/s41598-022-08083-6↗
  8. HIF-1 and NRF2; Key Molecules for Malignant Phenotypes of Pancreatic Cancer. Co-author DOI 10.3390/cancers14020411↗
  9. Senescent Human Pancreatic Stellate Cells Secrete CXCR2 Agonist CXCLs to Promote Proliferation and Migration of Human Pancreatic Cancer AsPC-1 and MIAPaCa-2 Ce… First author DOI 10.3390/ijms23169275↗
  10. Effective apparent diffusion coefficient parameters for differentiation between mass-forming autoimmune pancreatitis and pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00261-020-02795-x↗
  11. Nuclear Factor Erythroid 2-Related Factor 2 Depletion Sensitizes Pancreatic Cancer Cells to Gemcitabine via Aldehyde Dehydrogenase 3a1 Repression. First author DOI 10.1124/jpet.121.000744↗
  12. Abnormal Findings on "T1WI or DWI or MRCP:" An Effective Boolean Interpretation Model in Discriminating Small Pancreatic Ductal Adenocarcinoma from Control Gro… Co-author DOI 10.25259/jcis_158_2021↗
  13. Focal Parenchymal Atrophy of the Pancreas Is Frequently Observed on Pre-Diagnostic Computed Tomography in Patients with Pancreatic Cancer: A Case-Control Study. Co-author DOI 10.3390/diagnostics11091693↗
  14. Nrf2 Activation Sensitizes K-Ras Mutant Pancreatic Cancer Cells to Glutaminase Inhibition. Co-author DOI 10.3390/ijms22041870↗
  15. New-Onset or Exacerbation of Diabetes Mellitus Is a Clue to the Early Diagnosis of Pancreatic Cancer. Co-author DOI 10.1620/tjem.252.353↗
  16. Focal Parenchymal Atrophy and Fat Replacement Are Clues for Early Diagnosis of Pancreatic Cancer with Abnormalities of the Main Pancreatic Duct. Co-author DOI 10.1620/tjem.252.63↗
  17. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nat… Co-author DOI 10.1016/j.surg.2019.06.023↗
  18. Vasohibin-2 plays an essential role in metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.14041↗
  19. Exosomes derived from pancreatic cancer cells induce activation and profibrogenic activities in pancreatic stellate cells. Co-author DOI 10.1016/j.bbrc.2017.10.141↗
  20. Elucidating the link between collagen and pancreatic cancer: what's next? Co-author DOI 10.1080/17474124.2018.1448268↗
  21. Kindlin-2 in pancreatic stellate cells promotes the progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2017.01.008↗
  22. Exosomes Derived From Pancreatic Stellate Cells: MicroRNA Signature and Effects on Pancreatic Cancer Cells. Co-author DOI 10.1097/mpa.0000000000000722↗
  23. Clinicopathological Characteristics of Young Patients With Pancreatic Cancer: An Analysis of Data From Pancreatic Cancer Registry of Japan Pancreas Society. Co-author DOI 10.1097/mpa.0000000000000636↗
  24. Involvement of epithelial to mesenchymal transition in the development of pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00535-014-0997-0↗
  25. [Chronic pancreatitis is a risk factor of pancreatic cancer]. First author DOI 10.11405/nisshoshi.112.1464↗
  26. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer. Co-author DOI 10.3892/ijo.2014.2743↗
  27. [Desmoplastic reaction in pancreatic cancer]. First author PMID 25856980↗
  28. [Pancreatic cancer stem cell]. Co-author PMID 25985641↗
  29. Inflammation and pancreatic cancer: disease promoter and new therapeutic target. Co-author DOI 10.1007/s00535-013-0915-x↗
  30. MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX. Co-author DOI 10.1016/j.cellsig.2013.11.003↗
  31. CUB-domain containing protein 1 represses the epithelial phenotype of pancreatic cancer cells. First author DOI 10.1016/j.yexcr.2013.12.019↗
  32. The zinc transporter LIV-1 is a novel regulator of stemness in pancreatic cancer cells. Co-author DOI 10.3109/00365521.2013.865075↗
  33. miR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. Co-author DOI 10.1002/jcp.24280↗
  34. miR-210 regulates the interaction between pancreatic cancer cells and stellate cells. Co-author DOI 10.1016/j.bbrc.2013.06.097↗
  35. The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice. First author DOI 10.3109/00365521.2013.777776↗
  36. Alteration of pancreatic cancer cell functions by tumor-stromal cell interaction. Co-author DOI 10.3389/fphys.2013.00318↗
  37. Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer. Co-author DOI 10.3389/fphys.2013.00331↗
  38. The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2. Co-author DOI 10.1002/jcp.22781↗
  39. Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells. Co-author DOI 10.1016/j.bbrc.2012.04.014↗
  40. MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Co-author DOI 10.1158/1541-7786.mcr-11-0272↗
  41. Regulators of epithelial mesenchymal transition in pancreatic cancer. Co-author DOI 10.3389/fphys.2012.00254↗
  42. MSX2 in pancreatic tumor development and its clinical application for the diagnosis of pancreatic ductal adenocarcinoma. First author DOI 10.3389/fphys.2012.00430↗
  43. Biomarkers of pancreatic cancer. Co-author DOI 10.1159/000323479↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Atsushi Masamune · 39 shared papers, 2012–2026 · strength 4.50
  2. Ryotaro Matsumoto · 10 shared papers, 2020–2026 · strength 1.70
  3. Tooru Shimosegawa · 25 shared papers, 2011–2026 · strength 1.63
  4. Tetsuya Takikawa · 13 shared papers, 2012–2026 · strength 1.49
  5. Michiaki Unno · 11 shared papers, 2013–2026 · strength 1.48
  6. Kazuhiro Kikuta · 12 shared papers, 2012–2026 · strength 1.18
  7. Shinichi Egawa · 6 shared papers, 2013–2026 · strength 0.86
  8. Shin Miura · 9 shared papers, 2013–2026 · strength 0.85
  9. Sohei Satoi · 5 shared papers, 2016–2026 · strength 0.82
  10. Masamichi Mizuma · 5 shared papers, 2016–2026 · strength 0.82
  11. Takao Itoi · 5 shared papers, 2016–2026 · strength 0.82
  12. Naoki Yoshida · 8 shared papers, 2013–2022 · strength 0.73
  13. Kohei Nakata · 3 shared papers, 2026 · strength 0.71
  14. Ichiro Yasuda · 3 shared papers, 2026 · strength 0.71
  15. Yoshifumi Takeyama · 3 shared papers, 2026 · strength 0.71
  16. Ken Shirabe · 3 shared papers, 2026 · strength 0.71
  17. Kazuichi Okazaki · 3 shared papers, 2019–2026 · strength 0.54
  18. Yuzo Kodama · 2 shared papers, 2026 · strength 0.48
  19. Manabu Kawai · 2 shared papers, 2026 · strength 0.47
  20. Kennichi Satoh · 10 shared papers, 2012–2015 · strength 0.46
  21. Fumiya Kataoka · 3 shared papers, 2021–2022 · strength 0.42
  22. Hainan Ren · 2 shared papers, 2021 · strength 0.30
  23. Naoko Mori · 2 shared papers, 2021 · strength 0.30
  24. Kei Takase · 2 shared papers, 2021 · strength 0.30
  25. Kaori Hamamoto · 1 shared paper, 2026 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.